CA2863417C - Innate immune proteins as biomarkers for cns injury - Google Patents

Innate immune proteins as biomarkers for cns injury Download PDF

Info

Publication number
CA2863417C
CA2863417C CA2863417A CA2863417A CA2863417C CA 2863417 C CA2863417 C CA 2863417C CA 2863417 A CA2863417 A CA 2863417A CA 2863417 A CA2863417 A CA 2863417A CA 2863417 C CA2863417 C CA 2863417C
Authority
CA
Canada
Prior art keywords
injury
protein
patient
inflammasome
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2863417A
Other languages
English (en)
French (fr)
Other versions
CA2863417A1 (en
Inventor
Robert W. Keane
W. Dalton Dietrich
Juan Pablo De Rivero Vaccari
Stephanie ADAMCZAK
M. Ross Bullock
Allan LEVI
Michael Y. Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of CA2863417A1 publication Critical patent/CA2863417A1/en
Application granted granted Critical
Publication of CA2863417C publication Critical patent/CA2863417C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2863417A 2012-02-06 2013-02-06 Innate immune proteins as biomarkers for cns injury Active CA2863417C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261595254P 2012-02-06 2012-02-06
US61/595,254 2012-02-06
PCT/US2013/024941 WO2013119673A1 (en) 2012-02-06 2013-02-06 Innate immune proteins as biomarkers for cns injury

Publications (2)

Publication Number Publication Date
CA2863417A1 CA2863417A1 (en) 2013-08-15
CA2863417C true CA2863417C (en) 2020-07-28

Family

ID=48947960

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2863417A Active CA2863417C (en) 2012-02-06 2013-02-06 Innate immune proteins as biomarkers for cns injury

Country Status (6)

Country Link
US (4) US20150185232A1 (cg-RX-API-DMAC10.html)
EP (1) EP2812697B1 (cg-RX-API-DMAC10.html)
JP (1) JP6170071B2 (cg-RX-API-DMAC10.html)
CA (1) CA2863417C (cg-RX-API-DMAC10.html)
ES (1) ES2630905T3 (cg-RX-API-DMAC10.html)
WO (1) WO2013119673A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
US10725054B2 (en) 2014-04-08 2020-07-28 University Of Florida Research Foundation, Incorporated Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
WO2018126009A1 (en) 2016-12-29 2018-07-05 University Of Miami Method for modulating inflammasome activity and inflammation in the lung
KR101910269B1 (ko) * 2017-02-24 2018-10-19 성균관대학교산학협력단 인간 뇌 조직 유래 신경줄기세포의 고효율 분리 방법
CN111356924A (zh) * 2017-09-20 2020-06-30 迈阿密大学 检测作为神经障碍生物标记的炎性体蛋白的方法
US12287343B2 (en) * 2018-04-10 2025-04-29 Quanterix Corporation Quantification of neurofilament light chain in physiological samples
EP3818081A4 (en) 2018-07-03 2022-06-22 University of Miami COMPOSITIONS AND METHODS FOR TREATING INFLAMMASOME-RELATED DISEASES OR DISORDERS
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN109406795A (zh) * 2018-11-20 2019-03-01 昆明医科大学 一种轻型脑外伤的血清分子诊断标记物及应用
CN113366318A (zh) * 2019-01-31 2021-09-07 日内瓦大学 创伤性脑损伤(tbi)的前瞻性标志物
US20210100909A1 (en) * 2019-10-07 2021-04-08 United States Government As Represented By The Department Of Veterans Affairs Polymeric Methylprednisolone Conjugates and Uses Thereof
US20230296626A1 (en) * 2020-04-27 2023-09-21 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508707A (ja) * 2002-09-04 2006-03-16 ワシントン・ユニバーシティ 中枢神経系損傷の治療法
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
CA2715248A1 (en) * 2008-02-04 2009-08-13 Banyan Biomarkers, Inc. Process to diagnose or treat brain injury
US8404752B2 (en) * 2008-07-18 2013-03-26 Oxygen Biotherapeutics, Inc. Method of treating traumatic brain injury
US20120177632A1 (en) * 2011-01-10 2012-07-12 Shinohara Mari L Methods of optimizing disease treatment

Also Published As

Publication number Publication date
JP6170071B2 (ja) 2017-07-26
US20200363432A1 (en) 2020-11-19
ES2630905T3 (es) 2017-08-25
WO2013119673A1 (en) 2013-08-15
US20170003303A1 (en) 2017-01-05
US20230349929A1 (en) 2023-11-02
JP2015508887A (ja) 2015-03-23
EP2812697B1 (en) 2017-03-22
CA2863417A1 (en) 2013-08-15
US20150185232A1 (en) 2015-07-02
US12560618B2 (en) 2026-02-24
EP2812697A4 (en) 2015-08-26
EP2812697A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
US12560618B2 (en) Innate immune proteins as biomarkers for CNS injury
Tamhane et al. Review of Biomarkers in Ocular Matrices: Challenges and Opportunities: Tamhane, Cabrera-Ghayouri, Abelian and Viswanath
Carro et al. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
Babaloo et al. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels
KR102953162B1 (ko) 신경학적 장애의 바이오마커로서 인플라마솜 단백질의 검출 방법
CA2877975C (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
Cossu et al. Potential of PINK1 and PARKIN proteins as biomarkers for active multiple sclerosis: a Japanese cohort study
Wang et al. Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica
Ingram et al. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity
US20240060995A1 (en) Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients
Shaker et al. Serum levels of S100b, interleukin-6 and anti-transglutaminase Ii IgA as immune markers in a sample of Egyptian children with autistic spectrum disorders
Suzuki et al. Ratio of alpha 2-macroglobulin levels in cerebrospinal fluid and serum: an expression of neuroinflammation in acute disseminated encephalomyelitis
Nikolaus et al. Presence of anti-neuronal antibodies in children with neurological disorders beyond encephalitis
WO2024075029A1 (en) Method and kit for diagnosis, detection, monitoring and treatment of concussion or brain injury
WO2023212583A9 (en) Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients
US20220412994A1 (en) Biomarker of drug-induced cellular toxicity and depression
US11609236B2 (en) Blood biomarkers for severe traumatic brain injuries
Etemadifar et al. Seroprevalence of NMO-IgG among patients with neuromyelitis optica and opticospinal multiple sclerosis
US20200057078A1 (en) Melanotransferrin for use in the diagnosis of parkinson`s disease
Li et al. Immune-related biomarkers in the neuromyelitis optica spectrum disorder; pathogenesis and therapeutic approaches
Elshafey et al. Evaluation of the Relationship between Pemphigus Vulgaris Severity and the Serum Levels of IL33 and anti-Desmoglein-3 Antibody
鈴木雄一 Ratio of alpha2-macroglobulin levels in cerebrospinal fluid and serum: an expression of neuroinflammation in acute disseminated encephalomyelitis
Traboulsee et al. Epidemiology & Registry

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180110

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250131

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250131